Catalyst
Slingshot members are tracking this event:
FDA has placed Bluebird bio's (BLUE) studies of elivaldogene autotemcel (eli-cel, Lenti-D) for cerebral adrenoleukodystrophy (CALD) on clinical hold following safety report
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| BLUE |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 09, 2021
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Elivaldogene Autotemcel, Cerebral Adrenoleukodystrophy
